Info
Cancer Data For Good : A History of the Victorian Cancer Registry / / by Thomas Kehoe
| Cancer Data For Good : A History of the Victorian Cancer Registry / / by Thomas Kehoe |
| Autore | Kehoe Thomas |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Palgrave Macmillan, , 2022 |
| Descrizione fisica | 1 online resource (164 pages) |
| Disciplina | 636.80896994 |
| Soggetto topico |
Social medicine
Public health Medicine - History Health, Medicine and Society Medical Sociology Public Health History of Medicine |
| ISBN |
9789811949876
9789811949869 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Cancer Registration: A Neglected History -- 2. A Thirst for Data: Establishing the Victorian Cancer Registry, 1936-1945 -- 3.Post-War Recovery, Expansion, and Technological Advancement, 1945-1968 -- 4. The “Gray” Years: Technological Advancement and Legislative Change, 1968-1981 -- 5.New possibilities: The VCR as a population-based registry, 1981-1990 -- 6. The VCR as a Tool for Population Research and Intervention, 1991-2010 -- 7. Towards the future: New leadership and state of the art technology, 2011-2019. |
| Record Nr. | UNINA-9910624384003321 |
Kehoe Thomas
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Palgrave Macmillan, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Chemotherapy protocols and infusion sequence : schedule considerations in cancer treatment / / Iago Dillion Lima Cavalcanti
| Chemotherapy protocols and infusion sequence : schedule considerations in cancer treatment / / Iago Dillion Lima Cavalcanti |
| Autore | Cavalcanti Iago Dillion Lima |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (330 pages) |
| Disciplina | 636.80896994 |
| Soggetto topico |
Cancer - Chemotherapy
Infusion therapy |
| ISBN |
9783031108396
9783031108389 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: Polypharmacy in Cancer Therapy -- 1.1 Polypharmacy: Challenges in the Treatment of Chronic Diseases -- 1.2 Scenario of Polypharmacy in Cancer Treatment -- 1.3 Drug Interactions -- 1.3.1 Pharmacodynamic Interactions -- 1.3.2 Pharmacokinetic Interactions -- 1.4 Advantages in Drug Association -- 1.5 Risks of Polypharmacy -- References -- Chapter 2: Combined Therapy for the Treatment of Cancer -- 2.1 Anticancer Therapy -- 2.2 Combination Therapy in Cancer -- 2.2.1 Challenges in Combination Therapy -- 2.3 Toxicity of Combination Therapy for Cancer Treatment -- 2.3.1 Toxicity in the Treatment of Breast Cancer -- 2.3.2 Toxicity in the Treatment of Lung Cancer -- 2.3.3 Toxicity in the Treatment of Colorectal Cancer -- 2.3.4 Toxicity in the Treatment of Prostate Cancer -- 2.3.5 Toxicity in the Treatment of Cervical Cancer -- 2.3.6 Toxicity in the Treatment of Head and Neck Cancer -- 2.3.7 Toxicity in the Treatment of Lymphomas -- References -- Chapter 3: Importance of the Infusion Order in the Treatment of Cancer -- 3.1 Drug Infusion Therapy -- 3.1.1 Types of Infusion According to Administration Time -- 3.2 Dilution of Drugs and Their Stability -- 3.3 Risks of Chemotherapy Infusion -- 3.3.1 Drug Extravasation -- 3.3.1.1 Irritating Antineoplastics -- 3.3.1.2 Vesicant Antineoplastics -- 3.4 Concept and Importance of Infusion Order -- 3.4.1 Factors That May Influence in the Order of Infusion of Antineoplastic Agents -- References -- Chapter 4: Chemotherapeutic Protocols for the Treatment of Breast Cancer -- 4.1 Breast Cancer: Epidemiology -- 4.2 Pathophysiology of Breast Cancer -- 4.3 Molecular Subtypes of Breast Cancer -- 4.4 Breast Cancer Treatment Modalities -- 4.5 Adjuvant Chemotherapy -- 4.5.1 AC Protocol (Doxorubicin and Cyclophosphamide).
4.5.2 ACT, T-AC, or AC-T Protocol (Doxorubicin, Cyclophosphamide, and Paclitaxel) -- 4.5.3 ACTT Protocol (Doxorubicin, Cyclophosphamide, Paclitaxel, and Trastuzumab) -- 4.5.4 CMF Protocol (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) -- 4.5.5 FAC Protocol (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) -- 4.5.6 FEC Protocol (5-Fluorouracil, Epirubicin, and Cyclophosphamide) -- 4.5.7 FEC-D Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, and Docetaxel) -- 4.5.8 FEC-DT Protocol (5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.5.9 DAC (Docetaxel, Doxorubicin, and Cyclophosphamide) and DC (Docetaxel and Cyclophosphamide) Protocols -- 4.5.10 TDC Protocol (Trastuzumab, Docetaxel, and Cyclophosphamide) -- 4.5.11 DCARBT Protocol (Docetaxel, Carboplatin, and Trastuzumab) -- 4.6 Chemotherapy in Locally Advanced Breast Cancer -- 4.6.1 AC-DT Protocol (Doxorubicin, Cyclophosphamide, Docetaxel, and Trastuzumab) -- 4.6.2 CT-AC Protocol (Carboplatin, Paclitaxel, Doxorubicin, and Cyclophosphamide) -- 4.7 Chemotherapy in Advanced Breast Cancer -- 4.7.1 GEMD Protocol (Gemcitabine and Docetaxel) -- 4.7.2 GEMP Protocol (Gemcitabine and Cisplatin) -- 4.7.3 GEMT Protocol (Gemcitabine and Paclitaxel) -- 4.7.4 PTRAD Protocol (Pertuzumab, Trastuzumab, and Docetaxel) -- 4.7.5 PTRAT Protocol (Pertuzumab, Trastuzumab, and Paclitaxel) -- 4.7.6 TRVIN Protocol (Trastuzumab and Vinorelbine) -- References -- Chapter 5: Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer -- 5.1 Epidemiological Profile of Cancers of the Gastrointestinal Tract -- 5.2 Pathophysiology of Colorectal Cancer -- 5.2.1 Adjuvant Chemotherapy for the Treatment of Resectable Colorectal Cancer -- 5.2.1.1 CAPOX Protocol (Oxaliplatin and Capecitabine) -- 5.2.1.2 FL Protocol (5-Fluorouracil and Leucovorin). 5.2.1.3 FOLFOX Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.1.4 RALOX Protocol (Oxaliplatin and Raltitrexed) -- 5.2.2 Chemotherapy for the Treatment of Advanced Unresectable Colorectal Cancer -- 5.2.2.1 CAPB Protocol (Capecitabine and Bevacizumab) -- 5.2.2.2 CETIR Protocol (Cetuximab and Irinotecan) -- 5.2.2.3 FOLFIRI Protocol (Irinotecan, Leucovorin, 5-Fluorouracil, and 5-Fluorouracil in Continuous Infusion) -- 5.2.2.4 CAPIRI Protocol (Capecitabine and Irinotecan) -- 5.2.2.5 CAPIRIB Protocol (Capecitabine, Irinotecan, and Bevacizumab) -- 5.2.2.6 CAPOXB Protocol (Oxaliplatin, Bevacizumab, and Capecitabine) -- 5.2.2.7 FOLFIRIB Protocol (5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, Irinotecan, and Bevacizumab) -- 5.2.2.8 FOLFIRIPAN Protocol (5-Fluorouracil, Leucovorin, Irinotecan, and Panitumumab) -- 5.2.2.9 FOLFOXB Protocol (Oxaliplatin, Leucovorin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Bevacizumab) -- 5.2.2.10 FOLFOXPAN Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Panitumumab) -- 5.3 Pathophysiology of Esophageal and Stomach Cancers -- 5.3.1 Chemotherapy for the Treatment of Esophageal and Stomach Cancer -- 5.3.1.1 FOLFOXT Protocol (Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, Leucovorin, and Trastuzumab) -- 5.3.1.2 FLOT Protocol (Oxaliplatin, 5-Fluorouracil, Leucovorin, and Docetaxel) -- 5.3.1.3 CTRT Protocol (Carboplatin, Paclitaxel, and Radiotherapy) -- 5.3.1.4 FUC Protocol (5-Fluorouracil and Cisplatin) -- 5.3.1.5 CCAPRT Protocol (Cisplatin, Capecitabine, and Radiotherapy) -- 5.3.1.6 CCAPT Protocol (Cisplatin, Capecitabine, and Trastuzumab) -- 5.3.1.7 CFUT Protocol (Cisplatin, 5-Fluorouracil, and Trastuzumab). 5.3.1.8 CAPOXT Protocol (Capecitabine, Oxaliplatin, and Trastuzumab) -- 5.3.1.9 RAMP Protocol (Paclitaxel and Ramucirumab) -- 5.3.1.10 ECCAP Protocol (Epirubicin, Cisplatin, and Capecitabine) -- 5.4 Pathophysiology of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1 Chemotherapy for the Treatment of Pancreatic, Biliary Tract, and Gallbladder Cancers -- 5.4.1.1 GEMCIS Protocol (Gemcitabine and Cisplatin) -- 5.4.1.2 FOLFIRINOX Protocol (Irinotecan, Oxaliplatin, 5-Fluorouracil, 5-Fluorouracil in Continuous Infusion, and Leucovorin) -- 5.4.1.3 GEMCAP Protocol (Capecitabine and Gemcitabine) -- 5.4.1.4 GEMABR Protocol (Gemcitabine and Nab-Paclitaxel) -- 5.5 Pathophysiology of Liver Cancer -- 5.5.1 Chemotherapy for the Treatment of Liver Cancer -- 5.5.1.1 Nivolumab and Ipilimumab Protocol -- 5.5.1.2 Atezolizumab and Bevacizumab Protocol -- 5.6 Pathophysiology of Carcinoid and Neuroendocrine Tumors -- 5.6.1 Chemotherapy for the Treatment of Carcinoid and Neuroendocrine Tumors -- 5.6.1.1 ETCIS Protocol (Etoposide and Cisplatin) -- 5.6.1.2 DS Protocol (Doxorubicin and Streptozotocin) -- 5.7 Pathophysiology of Anal Cancer -- 5.7.1 Chemotherapy in the Treatment of Anal Cancer -- 5.7.1.1 FUMRT Protocol (5-Fluorouracil, Mitomycin C, and Radiotherapy) -- 5.7.1.2 CAPMRT Protocol (Capecitabine, Mitomycin C, and Radiotherapy) -- References -- Chapter 6: Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer -- 6.1 Epidemiological Profile of Genitourinary Cancers -- 6.2 Pathophysiology of Bladder Cancer -- 6.2.1 Chemotherapy for the Treatment of Bladder Cancer -- 6.2.1.1 BCGIFN Protocol (BCG and Interferon) -- 6.2.1.2 GEMDOC Protocol (Gemcitabine and Docetaxel) -- 6.2.1.3 MVAC Protocol (Methotrexate, Vinblastine, Doxorubicin, and Cisplatin) -- 6.3 Pathophysiology of Prostate Cancer -- 6.3.1 Chemotherapy for the Treatment of Prostate Cancer. 6.4 Testicular Cancer -- 6.4.1 Chemotherapy for the Treatment of Testicular Cancer -- 6.4.1.1 BEP Protocol (Bleomycin, Etoposide, and Cisplatin) -- 6.4.1.2 VIP Protocol (Etoposide, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.3 TAXGEM Protocol (Paclitaxel and Gemcitabine) -- 6.4.1.4 TIP Protocol (Paclitaxel, Cisplatin, Ifosfamide, and Mesna) -- 6.4.1.5 VEIP Protocol (Vinblastine, Cisplatin, Ifosfamide, and Mesna) -- 6.5 Pathophysiology of Kidney Cancer -- 6.5.1 Chemotherapy for the Treatment of Kidney Cancer -- 6.5.1.1 PEMAX Protocol (Pembrolizumab and Axitinib) -- 6.5.1.2 Avelumab and Axitinib Protocol -- References -- Chapter 7: Chemotherapeutic Protocols for the Treatment of Gynecological Cancer -- 7.1 Epidemiological Profile of Gynecological Cancers -- 7.2 Pathophysiology of Ovarian Cancer -- 7.2.1 Chemotherapy for the Treatment of Epithelial Ovarian Cancer -- 7.2.1.1 CABR Protocol (Carboplatin and Abraxane) -- 7.2.1.2 CAPBEV Protocol (Carboplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.3 CISP Protocol (Cisplatin and Paclitaxel) -- 7.2.1.4 CISPBEV Protocol (Cisplatin, Paclitaxel, and Bevacizumab) -- 7.2.1.5 CAD Protocol (Carboplatin and Docetaxel) -- 7.2.1.6 CAG Protocol (Carboplatin and Gemcitabine) -- 7.2.1.7 PLDC Protocol (Pegylated Liposomal Doxorubicin and Carboplatin) -- 7.2.1.8 BEVG Protocol (Bevacizumab and Gemcitabine) -- 7.2.1.9 BEVPLD Protocol (Bevacizumab and Pegylated Liposomal Doxorubicin) -- 7.2.1.10 BEVP Protocol (Bevacizumab and Paclitaxel) -- 7.2.2 Chemotherapy for the Treatment of Non-epithelial Ovarian Cancer -- 7.3 Pathophysiology of Cervical Cancer -- 7.3.1 Chemotherapy for the Treatment of Cervical Cancer -- 7.4 Pathophysiology of Endometrial Cancer -- 7.4.1 Chemotherapy for the Treatment of Endometrial Cancer -- 7.5 Pathophysiology of Gestational Trophoblastic Neoplasia. 7.5.1 Chemotherapy for the Treatment of Gestational Trophoblastic Neoplasia. |
| Record Nr. | UNINA-9910619286503321 |
|
Cavalcanti Iago Dillion Lima
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Computational mathematics modeling in cancer analysis : irst international workshop, CMMCA 2022, held in conjunction with MICCAI 2022, Singapore, September 18, 2022, proceedings / / edited by Wenjian Qin [and three others]
| Computational mathematics modeling in cancer analysis : irst international workshop, CMMCA 2022, held in conjunction with MICCAI 2022, Singapore, September 18, 2022, proceedings / / edited by Wenjian Qin [and three others] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (171 pages) |
| Disciplina | 636.80896994 |
| Collana | Lecture Notes in Computer Science Ser. |
| Soggetto topico | Cancer - Imaging |
| ISBN | 3-031-17266-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996490353903316 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Computational Mathematics Modeling in Cancer Analysis : First International Workshop, CMMCA 2022, Held in Conjunction with MICCAI 2022, Singapore, September 18, 2022, Proceedings / / edited by Wenjian Qin, Nazar Zaki, Fa Zhang, Jia Wu, Fan Yang
| Computational Mathematics Modeling in Cancer Analysis : First International Workshop, CMMCA 2022, Held in Conjunction with MICCAI 2022, Singapore, September 18, 2022, Proceedings / / edited by Wenjian Qin, Nazar Zaki, Fa Zhang, Jia Wu, Fan Yang |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (171 pages) |
| Disciplina |
636.80896994
616.99400113 |
| Collana | Lecture Notes in Computer Science |
| Soggetto topico |
Image processing - Digital techniques
Computer vision Computer engineering Computer networks Machine learning Computers Computer Imaging, Vision, Pattern Recognition and Graphics Computer Engineering and Networks Machine Learning Computing Milieux |
| ISBN |
9783031172663
3031172663 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cellular Architecture on Whole Slide Images Allows the Prediction of Survival in Lung Adenocarcinoma -- Is More Always Better? Effects of Patch Sampling in Distinguishing Chronic Lymphocytic Leukemia from Transformation to Diffuse Large B-cell Lymphoma -- Repeatability of Radiomic Features against Simulated Scanning Position Stochasticity across Imaging Modalities and Cancer Subtypes: A Retrospective Multi-Institutional Study on Head-and-Neck Cases -- MLCN: Metric Learning Constrained Network for Whole Slide Image Classification with Bilinear Gated Attention Mechanism -- NucDETR: End-to-End Transformer for Nucleus Detection in Histopathology Images -- Self-supervised learning based on a pre-trained method for the subtype classification of spinal tumors -- CanDLE: Illuminating Biases in Transcriptomic Pan-Cancer Diagnosis -- Cross-Stream Interactions: Segmentation of Lung Adenocarcinoma Growth Patterns -- Modality-collaborative AI model Ensemble for Lung Cancer Early Diagnosis -- Clustering-based Multi-instance Learning Network for Whole Slide Image Classification -- Multi-task Learning-driven Volume and Slice Level Contrastive Learning for 3D Medical Image Classification -- Light Annotation Fine Segmentation: Histology Image Segmentation based on VGG Fusion with Global Normalisation CAM -- Tubular Structure-Aware Convolutional Neural Networks for Organ at Risks Segmentation in Cervical Cancer Radiotherapy -- Automatic Computer-aided Histopathologic Segmentation for Nasopharyngeal Carcinoma using Transformer Framework -- Accurate Breast Tumor Identification UsingComputational Ultrasound Image Features. |
| Record Nr. | UNINA-9910595023903321 |
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Target Volume Delineation and Field Setup : A Practical Guide for Conformal and Intensity-Modulated Radiation Therapy / / edited by Nancy Y. Lee, Jiade J. Lu, Yao Yu
| Target Volume Delineation and Field Setup : A Practical Guide for Conformal and Intensity-Modulated Radiation Therapy / / edited by Nancy Y. Lee, Jiade J. Lu, Yao Yu |
| Edizione | [2nd ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (437 pages) |
| Disciplina |
636.80896994
616.9940642 |
| Collana | Practical Guides in Radiation Oncology |
| Soggetto topico |
Medical radiology
Oncology Internal medicine Radiology Radiation Oncology Internal Medicine Càncer Radioteràpia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-99590-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1.Nasopharyngeal Cancer -- 2.Oropharyngeal Cancer -- 3. Stereotactic Body Radiotherapy for Head and Neck Cancer -- 4. Larynx Cancer -- 5.Hypopharyngeal Cancer -- 6.Oral Cavity Cancer -- 7.Nasal cavity and Paranasal Sinus Cancer -- 8.Major Salivary Glands -- 9.Thyroid Cancer -- 10.Squamous Cell Carcinomas of Unknown Primary in the Head and Neck -- 11.Early Breast Cancer -- 12.Regional Lymph Node Irradiation for Breast Cancer -- 13.Lung Cancer -- 14.Esophageal Cancer -- 15.Gastric Cancer -- 16.Pancreatic Cancer -- 17.Hepatocellular Cancer -- 18.Rectal Cancer -- 19.Anal Cancer -- 20.Postoperative Therapy for Cervical, Vaginal, and Endometrial Cancer -- 21.Definitive Therapy for Cervical, Vaginal, and Endometrial Cancer -- 22.Image-guided brachytherapy Ovarian Cancer -- 23.Vulvar Cancer -- 24.Advanced Technologies and Treatment Techniques for Gynecologic Malignancies -- 25.Prostate Adenocarcinoma -- 26.Bladder Cancer -- 27.Testicular Seminoma -- 28.Brain Metastases -- 29.Benign Tumors of theCNS -- 30.Malignant tumors of the CNS -- 31.Hodgkin's and Non-hodgkin's Lymphoma -- 32.Soft Tissue Sarcoma -- 33.Pediatric Sarcoma -- 34.Pediatric Brain Tumors. |
| Record Nr. | UNINA-9910620196103321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||